Guizhou Bailing Group Pharmaceutical Co Ltd Total Liabilities
Guizhou Bailing Group Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has total liabilities worth CN¥2.75 Billion CNY (≈ $402.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002424 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
Total liabilities of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Guizhou Bailing Group Pharmaceutical Co to see how much of total assets are deployed in long-term investments.
Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Bailing Group Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strait Innovation Internet Co Ltd
SHE:300300
|
China | CN¥745.66 Million |
|
Oppenheimer Holdings Inc
NYSE:OPY
|
USA | $2.90 Billion |
|
Guan Chong Bhd
KLSE:5102
|
Malaysia | RM4.82 Billion |
|
Prodea Real Estate Investment Co.
AT:PRODEA
|
Greece | €1.74 Billion |
|
Elemental Royalty Corporation
NASDAQ:ELE
|
USA | $135.71 Million |
|
Hotel Shilla
KO:008770
|
Korea | ₩2.47 Trillion |
|
Cobram Estate Olives Ltd
AU:CBO
|
Australia | AU$358.24 Million |
|
Drägerwerk AG & Co. KGaA
XETRA:DRW8
|
Germany | €1.52 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Guizhou Bailing Group Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002424 current and non-current assets.
Liquidity & Leverage Metrics
Guizhou Bailing Group Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Guizhou Bailing Group Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Bailing Group Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total liabilities of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.02 Billion ≈ $442.32 Million |
-23.20% |
| 2024-12-31 | CN¥3.94 Billion ≈ $575.92 Million |
+2.98% |
| 2023-12-31 | CN¥3.82 Billion ≈ $559.25 Million |
+31.90% |
| 2022-12-31 | CN¥2.90 Billion ≈ $423.99 Million |
+14.56% |
| 2021-12-31 | CN¥2.53 Billion ≈ $370.09 Million |
-18.74% |
| 2020-12-31 | CN¥3.11 Billion ≈ $455.46 Million |
+6.86% |
| 2019-12-31 | CN¥2.91 Billion ≈ $426.23 Million |
+41.98% |
| 2018-12-31 | CN¥2.05 Billion ≈ $300.21 Million |
+51.35% |
| 2017-12-31 | CN¥1.36 Billion ≈ $198.35 Million |
+15.79% |
| 2016-12-31 | CN¥1.17 Billion ≈ $171.30 Million |
+0.87% |
| 2015-12-31 | CN¥1.16 Billion ≈ $169.82 Million |
-4.66% |
| 2014-12-31 | CN¥1.22 Billion ≈ $178.13 Million |
-9.95% |
| 2013-12-31 | CN¥1.35 Billion ≈ $197.81 Million |
+12.89% |
| 2012-12-31 | CN¥1.20 Billion ≈ $175.23 Million |
+11.04% |
| 2011-12-31 | CN¥1.08 Billion ≈ $157.81 Million |
+13.22% |
| 2010-12-31 | CN¥952.49 Million ≈ $139.38 Million |
+113.81% |
| 2009-12-31 | CN¥445.48 Million ≈ $65.19 Million |
+38.90% |
| 2008-12-31 | CN¥320.72 Million ≈ $46.93 Million |
+1.54% |
| 2007-12-31 | CN¥315.87 Million ≈ $46.22 Million |
-- |
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more